- Home
- SNDR vs LEGN Comparison
SNDR vs LEGN Comparison
Compare SNDR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDR | LEGN |
|---|---|---|
| Founded | 1935 | 2014 |
| Country | United States | United States |
| Employees | 19000 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNDR | LEGN |
|---|---|---|
| Price | $37.21 | $32.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $27.83 | ★ $61.33 |
| AVG Volume (30 Days) | 933.7K | ★ 2.8M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $5,674,300,000.00 | N/A |
| Revenue This Year | $5.11 | $42.68 |
| Revenue Next Year | $6.05 | $30.52 |
| P/E Ratio | $309.17 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $16.24 |
| 52 Week High | $37.11 | $45.30 |
Technical Indicators
Market Signals| Indicator | SNDR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 76.08 | 60.90 |
| Support Level | $26.88 | $31.84 |
| Resistance Level | N/A | $34.54 |
| Average True Range (ATR) | 1.06 | 2.59 |
| MACD | 0.24 | 0.42 |
| Stochastic Oscillator | 87.35 | 63.44 |
Price Performance
Historical ComparisonAbout SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.